Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Coherus Oncology (CHRS) EPS (Basic): 2012-2024

Historic EPS (Basic) for Coherus Oncology (CHRS) over the last 13 years, with Dec 2024 value amounting to $0.25.

  • Coherus Oncology's EPS (Basic) rose 7.32% to -$0.38 in Q3 2025 from the same period last year, while for Sep 2025 it was $3.43, marking a year-over-year increase of 576.39%. This contributed to the annual value of $0.25 for FY2024, which is 109.88% up from last year.
  • Latest data reveals that Coherus Oncology reported EPS (Basic) of $0.25 as of FY2024, which was up 109.88% from -$2.53 recorded in FY2023.
  • Coherus Oncology's EPS (Basic)'s 5-year high stood at $1.85 during FY2020, with a 5-year trough of -$3.81 in FY2021.
  • Moreover, its 3-year median value for EPS (Basic) was -$2.53 (2023), whereas its average is -$2.01.
  • Its EPS (Basic) has fluctuated over the past 5 years, first slumped by 305.95% in 2021, then spiked by 109.88% in 2024.
  • Over the past 5 years, Coherus Oncology's EPS (Basic) (Yearly) stood at $1.85 in 2020, then tumbled by 305.95% to -$3.81 in 2021, then increased by 1.31% to -$3.76 in 2022, then spiked by 32.71% to -$2.53 in 2023, then spiked by 109.88% to $0.25 in 2024.